Intervention

68Ga-PSMA-11

ClinicalTrials.gov intervention label

Explore related research

Search across original and mapped records

Search results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 28 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials28
Recruiting5
Common conditions25
Lead sponsors shown15
Advertisement

Clinical trials

28 shown
PSMA PET Combined With MRI for the Detection of PCaNCT07052214 · 2025-08-18
RECRUITING
68Ga-P16-093 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Primary Prostate Cancer PatientsNCT05324332 · 2022-04-15
RECRUITING
Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate CancerNCT04946370 · 2021-08-12
RECRUITING
Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate CancerNCT04886986 · 2021-06-30
RECRUITING
68Ga-PSMA-11 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRINCT07209878 · 2020-01-10
RECRUITING
Response With Interim PSMA PET in Metastatic Castration-sensitive Prostate Cancer for Optimization of Adaptive Metastasis-directed Radiotherapy DeliveryNCT07674771 · 2026-10-01
NOT_YET_RECRUITING
Imaging Characteristics of Different ⁶⁸Ga-PSMA Probes in Prostate CancerNCT07365397 · 2026-01-19
NOT_YET_RECRUITING
Prospective Clinical Trial of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate CancerNCT07117760 · 2025-04-22
ACTIVE_NOT_RECRUITING
Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal FunctionNCT06004661 · 2024-04-04
ACTIVE_NOT_RECRUITING
Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLTNCT05983198 · 2023-11-07
ACTIVE_NOT_RECRUITING
68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese PatientsNCT05847348 · 2023-07-19
UNKNOWN
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPCNCT05670106 · 2023-05-16
COMPLETED
Head-to-head Comparison of 68Ga-PSMA-11 and 18F-PSMA-1007NCT05079828 · 2022-07-07
COMPLETED
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in JapanNCT05114746 · 2022-01-25
COMPLETED
68Ga-P15-041 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Prostate Bone MetastasisNCT05627778 · 2021-11-01
UNKNOWN
68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate CancerNCT04716725 · 2021-09-28
TERMINATED
Diagnostic Performance of PET/CT-PSMA in Patients With Non-prostatic PSMA-expressing NeoplasmsNCT06835244 · 2021-09-17
ENROLLING_BY_INVITATION
177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate CancerNCT04689828 · 2021-06-15
ACTIVE_NOT_RECRUITING
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)NCT04720157 · 2021-06-09
ACTIVE_NOT_RECRUITING
[68Ga]Ga-PSMA-11 PET/CT in the Assessment of High Risk and Recurrent Prostate CancerNCT04484701 · 2021-02-01
ACTIVE_NOT_RECRUITING
68Ga-PSMA-11 PET/CT in Patients With Various Types of CancerNCT04831541 · 2020-10-10
UNKNOWN
A Trial of CTT1403 for Metastatic Castration Resistant Prostate CancerNCT03822871 · 2019-04-01
COMPLETED
68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate CancerNCT03809078 · 2019-01-14
COMPLETED
Place of 68Ga-PSMA-11 PET-CT in the Therapeutic Decision at the End of the Initial Staging for High Risk Prostate Cancer PatientsNCT03344822 · 2018-01-02
UNKNOWN
68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial TreatmentNCT02673151 · 2017-05-20
COMPLETED
68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing SurgeryNCT02678351 · 2016-04-18
COMPLETED
Clinical Use of 68Ga PSMA-11 PET/CT in Diagnosing, Staging and Restaging Prostate CancerNCT05002465
NO_LONGER_AVAILABLE
Expanded Access to Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrent Prostate CancerNCT05415228
NO_LONGER_AVAILABLE

Common conditions

Leading sponsors

Trial status mix

COMPLETED7
ACTIVE_NOT_RECRUITING6
RECRUITING5
UNKNOWN4
NO_LONGER_AVAILABLE2
NOT_YET_RECRUITING2
ENROLLING_BY_INVITATION1
TERMINATED1

Phase mix

PHASE212
PHASE38
PHASE16
NA3
EARLY_PHASE12
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.